Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Mol Psychiatry ; 27(8): 3533-3543, 2022 08.
Article de Anglais | MEDLINE | ID: mdl-35418601

RÉSUMÉ

Liver-generated plasma apolipoprotein E (apoE) does not enter the brain but nonetheless correlates with Alzheimer's disease (AD) risk and AD biomarker levels. Carriers of APOEε4, the strongest genetic AD risk factor, exhibit lower plasma apoE and altered brain integrity already at mid-life versus non-APOEε4 carriers. Whether altered plasma liver-derived apoE or specifically an APOEε4 liver phenotype promotes neurodegeneration is unknown. Here we investigated the brains of Fah-/-, Rag2-/-, Il2rg-/- mice on the Non-Obese Diabetic (NOD) background (FRGN) with humanized-livers of an AD risk-associated APOE ε4/ε4 versus an APOE ε2/ε3 genotype. Reduced endogenous mouse apoE levels in the brains of APOE ε4/ε4 liver mice were accompanied by various changes in markers of synaptic integrity, neuroinflammation and insulin signaling. Plasma apoE4 levels were associated with unfavorable changes in several of the assessed markers. These results propose a previously unexplored role of the liver in the APOEε4-associated risk of neurodegenerative disease.


Sujet(s)
Maladie d'Alzheimer , Maladies neurodégénératives , Animaux , Souris , Apolipoprotéine E4/génétique , Souris de lignée NOD , Apolipoprotéines E/génétique , Encéphale/métabolisme , Maladie d'Alzheimer/génétique , Génotype , Marqueurs biologiques , Foie/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...